Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shi-Ming Tu

Showing results (101-110 of 131) with videos related to

Pageof 14
Sort By:
Molecular Cancer Research : MCR|July 20, 2007
Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cellsChien-Jui Cheng, Xiang-cang Ye, Funda Vakar-Lopez, et al.
Cancer|May 27, 2020
Patterns of metastases of prostatic ductal adenocarcinomaWeranja K B Ranasinghe, Nathan A Brooks, Mohamed A Elsheshtawi, et al.
Nature Reviews. Urology|April 7, 2021
Optimizing the diagnosis and management of ductal prostate cancerWeranja Ranasinghe, Daniel D Shapiro, Miao Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinomaEric Jonasch, Christopher G Wood, Surena F Matin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancerSue-Hwa Lin, Yu-Chen Lee, Michel B Choueiri, et al.
Cancer|August 27, 2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancerMehmet Asim Bilen, Marcella M Johnson, Paul Mathew, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2017
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapyMehmet Asim Bilen, Kenneth R Hess, Sumit K Subudhi, et al.
Cancers|March 10, 2022
Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and ImplicationsJoseph A Moore, Rebecca S Slack, Michael J Lehner, et al.
Journal of Clinical Medicine|June 27, 2024
Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable CancerJamaal C Jackson, Darren Sanchez, Andrew C Johns, et al.
BJUI Compass|December 26, 2022
Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeriesJoseph A Moore, Michael J Lehner, Simone Anfossi, et al.
Pageof 14

Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Molecular Cancer Research : MCR|July 20, 2007
Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cellsChien-Jui Cheng, Xiang-cang Ye, Funda Vakar-Lopez, et al.
Cancer|May 27, 2020
Patterns of metastases of prostatic ductal adenocarcinomaWeranja K B Ranasinghe, Nathan A Brooks, Mohamed A Elsheshtawi, et al.
Nature Reviews. Urology|April 7, 2021
Optimizing the diagnosis and management of ductal prostate cancerWeranja Ranasinghe, Daniel D Shapiro, Miao Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinomaEric Jonasch, Christopher G Wood, Surena F Matin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancerSue-Hwa Lin, Yu-Chen Lee, Michel B Choueiri, et al.
Cancer|August 27, 2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancerMehmet Asim Bilen, Marcella M Johnson, Paul Mathew, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2017
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapyMehmet Asim Bilen, Kenneth R Hess, Sumit K Subudhi, et al.
Cancers|March 10, 2022
Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and ImplicationsJoseph A Moore, Rebecca S Slack, Michael J Lehner, et al.
Journal of Clinical Medicine|June 27, 2024
Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable CancerJamaal C Jackson, Darren Sanchez, Andrew C Johns, et al.
BJUI Compass|December 26, 2022
Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeriesJoseph A Moore, Michael J Lehner, Simone Anfossi, et al.
Pageof 14